Welcome to our dedicated page for Ginkgo Bioworks Holdings news (Ticker: DNA), a resource for investors and traders seeking the latest updates and insights on Ginkgo Bioworks Holdings stock.
Ginkgo Bioworks Holdings, Inc. reports developments around cell engineering, autonomous laboratory infrastructure, and contract research services that make biological R&D more programmable. Its updates cover Ginkgo Cloud Lab, Datapoints and Solutions services, Reconfigurable Automation Carts, Catalyst automation software, and AI-enabled workflows for protein engineering, nucleic acid design, cell-free systems, and biological manufacturing.
Company news also includes financial-results presentations, customer and research collaborations, agricultural biotechnology manufacturing work, and capital or governance updates. Following the completed divestiture of its Biosecurity business, recurring coverage centers on Ginkgo's autonomous lab strategy, remote wet-lab access, microbial strain engineering, fermentation processes, and the commercial use of lab-generated biological data.
Ginkgo Bioworks (DNA) announced that its Ginkgo Datapoints offering has entered into an agreement with Lilly’s AI/ML drug discovery platform TuneLab. Ginkgo Datapoints will provide biological discovery data generation services, including small molecule ADME and antibody developability testing, to companies participating in TuneLab. The goal is to link TuneLab’s predictive AI models with Ginkgo’s automated, high-throughput lab capabilities, turning AI-generated hypotheses into validated experimental data in days instead of months. Standardized assay protocols across the TuneLab network are expected to make models learn more efficiently and allow new TuneLab members to submit Datapoints-generated data for additional model benefits.
Ginkgo Bioworks (DNA) has been awarded a subcontract for up to $17.5 million under ARPA-H’s Genetic Medicines and Individualized Manufacturing for Everyone (GIVE) program, as part of the ESCALATOR initiative to develop an autonomous, benchtop RNA drug manufacturing system.
Ginkgo will supply automation hardware, systems integration and control software that link four custom manufacturing modules and an in-line quality control subsystem of about twenty instruments. Using its Reconfigurable Automation Carts and Catalyst software, Ginkgo plans to unify control, automate manufacturing and QC protocols, and enable automated product quality decisions suitable for GMP environments. Work is expected to start following a technical kickoff later this month.
Ginkgo Bioworks (NYSE: DNA), Tangible Scientific, and Inductive Bio launched ADME-One™, a high-throughput Tier 1 ADME platform integrating automated data generation, AI-driven human PK projection, and compound management.
The U.S.-based service targets earlier, data-rich small molecule decision-making at pricing described as several times lower than typical industry options.
Ginkgo Bioworks (NYSE: DNA) reported Q1 2026 results and completed the divestiture of its Biosecurity business on April 3, 2026, presenting that unit as discontinued operations.
Key metrics: Q1 revenue $19M (down 49% vs. prior year), GAAP net loss $76M, Adjusted EBITDA $(42)M, and $373M in cash, cash equivalents and marketable securities as of March 31, 2026. Full‑year 2026 cash burn is reaffirmed at $(150)M–$(125)M. Management reiterated focus on scaling its Nebula autonomous lab.
Ginkgo Bioworks (NYSE: DNA) will present first-quarter 2026 results on Thursday, May 7, 2026 at 4:30 p.m. ET with a post-market presentation and Q&A. The live webcast and presentation details will be available on the company investor relations site, and a replay will be posted afterward.
Investors can submit questions in advance via X @Ginkgo with hashtag #GinkgoResults or by email to investors@ginkgobioworks.com.
Ginkgo Bioworks (NYSE: DNA) launched Ginkgo Cloud Lab on March 2, 2026, a web interface giving researchers remote access to Ginkgo's autonomous lab infrastructure.
Cloud Lab runs on proprietary Reconfigurable Automation Carts (RACs), a fleet of >70 instruments, and an AI agent called EstiMate that assesses protocol compatibility and provides pricing. Ginkgo said it will migrate R&D services onto its Nebula autonomous lab and decommission traditional benches.
Ginkgo Bioworks (NYSE: DNA) reported fourth-quarter 2025 revenue of $33M (down 24% YoY) and GAAP net loss of $81M. Full-year 2025 revenue was $170M (down 25%); GAAP net loss $313M. Adjusted EBITDA improved to $(167)M FY. Cash and marketable securities totaled $423M at year-end. The company announced a planned divestiture of its biosecurity business to a consortium for a minority equity stake, expected to close in H1 2026, and will concentrate investments on building and commercializing autonomous labs. 2026 cash burn guidance: $(150)M–$(125)M.
Ginkgo Bioworks (NYSE: DNA) will present its fourth quarter and full year 2025 results on Thursday, February 26, 2026 at 4:30 p.m. ET. The company said the presentation will include a review of business performance for the period ended December 31, 2025, with a live webcast and later replay available on its investor relations website.
Investors can submit questions in advance via X (hashtag #GinkgoResults) or by emailing investors@ginkgobioworks.com.
Ginkgo Bioworks (NYSE: DNA) and Invaio Sciences announced a collaboration on Feb 18, 2026 to develop microbial manufacturing technology for peptide-based agricultural products.
The program will optimize Ginkgo's engineered strains, fermentation processes, and autonomous lab protocols to enable commercial-scale peptide production that meets growers' cost and usability needs.
Ginkgo Bioworks (NYSE: DNA) and OpenAI report an autonomous laboratory using GPT-5 that cut cell-free protein synthesis reaction costs by 40% versus prior state of the art, producing sfGFP at $422 per gram versus $698 per gram. The system ran 36,000 reaction compositions across six iterative cycles and generated ~150,000 data points.
The collaborative workflow combined GPT-5 reasoning, Ginkgo's cloud laboratory infrastructure, validation via a Pydantic model, and limited human oversight; the AI-improved reagent mix is now commercially available.